NCT05622591View on ClinicalTrials.gov

ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

June 7, 2024

Primary Completion Date

June 7, 2024

Study Completion Date

June 7, 2024

Conditions

Acute Myeloid LeukemiaAML, ChildhoodRelapsed Pediatric AMLRefractory Pediatric AML

Interventions

DRUG

ELU001

Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)

Sponsors

Lead Sponsor

Elucida Oncology

All Listed Sponsors

lead

Elucida Oncology

INDUSTRY